Dialysis News and Research

Latest Dialysis News and Research

Time trends in initiation of chronic dialysis in the U.S.

It has become increasingly clear that patients in the United States are starting dialysis at higher and higher levels of kidney function. A team of researchers, led by Dr. Ann O'Hare, University of Washington associate professor of medicine and affiliate investigator at Group Health Research Institute, set out recently to find out what this means for patients, and how much earlier patients are starting dialysis compared with past practices.

12 Oct 2011

Takeda, Affymax announce data from multiple studies of peginesatide on anemia

Affymax, Inc. and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide have been accepted for presentation at the American Society of Nephrology (ASN) Kidney Week 2011 taking place November 8-13, 2011 in Philadelphia, Pa.

11 Oct 2011

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved JUVISYNC(sitagliptin and simvastatin), a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA (sitagliptin), with the cholesterol-lowering medication ZOCOR.

10 Oct 2011

Health Canada approves Trajenta (linagliptin) for type 2 diabetes

Boehringer Ingelheim Canada and Eli Lilly Canada today announced that Health Canada has approved Trajenta (linagliptin), a new oral therapy to improve glycemic control in Canadian adults with type 2 diabetes.

3 Oct 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers Squibb Company announced today that 22 abstracts on the Company's research in liver disease have been accepted for presentation at The Liver Meeting 2011, the 62nd annual meeting of the American Association for the Study of Liver Diseases, in San Francisco, November 4 - 8.

1 Oct 2011

Dialysis patients with kidney failure more likely to develop serious complications from flu

For most people, the flu is a temporary setback that makes them feel under the weather for a week or two. For dialysis patients with kidney failure, however, the flu is a serious health threat that can lead to pneumonia and other life-threatening complications.

1 Oct 2011

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

The U.S. Food and Drug Administration today approved Soliris (eculizumab) to treat patients with atypical Hemolytic Uremic Syndrome (aHUS), a rare and chronic blood disease that can lead to kidney (renal) failure and is also associated with increased risk of death and stroke.

26 Sep 2011

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that the therapeutic indication for Soliris® (eculizumab) be extended to include the treatment of pediatric and adult patients with atypical hemolytic uremic syndrome (aHUS) in Europe.

23 Sep 2011

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

Celgene International Sàrl was notified today that the E.U. Committee for Medicinal Products for Human Use (CHMP), on behalf of the European Medicines Agency (EMA) has concluded an Article 20 review of REVLIMID and issued a positive opinion for the use of REVLIMID in combination with dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

23 Sep 2011

NYT: Ethics probe involves kidney transplant center, Rep. Berkley

In 2008 Ms. Berkley helped lead an effort to block a move by federal regulators to close Nevada's only kidney transplant center, which her husband's medical practice helps run under a $738,000-a-year contract. She also successfully pushed regulators, as recently as March, to reverse a plan to cut Medicare reimbursement to dialysis centers, including the dozen her husband's medical practice owns.

23 Sep 2011

First Edition: September 22, 2011

In today's headlines, reports that young adults are making gains in health coverage rates.

22 Sep 2011

Long-term immunosuppressants improve survival for lupus patients with ESKD

Researchers at Albert Einstein College of Medicine of Yeshiva University have shown that close supervision by rheumatologists and the use of immunosuppressant drugs improve the survival of lupus patients with end-stage kidney disease—a finding that could reverse long-standing clinical practice.

21 Sep 2011

Keryx completes enrollment in Zerenex Phase 3 long-term study for hyperphosphatemia

Keryx Biopharmaceuticals today announced completion of patient enrollment in the long-term study component of its Phase 3 registration program of Zerenex, the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.

20 Sep 2011

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes compared to the addition of placebo (with or without metformin) from 24 to 52 weeks.

16 Sep 2011

Demand for kidney transplant and dialysis increases due to diabetes prevalence

A survey reveals that the need for kidney transplants and dialysis is expected to soar by 2020 mainly due to a rise in diabetics developing chronic kidney disease and needing treatment. The total number of Australians being treated for end-stage kidney disease is forecast to rise by up to 80 per cent to about 4300 in the coming decade. While the fact that Australia's population is ageing and growing means more people are likely to develop end-stage kidney disease, the number of diabetics with the condition is also on the rise.

15 Sep 2011

KAI enters KAI-4169 development and commercialization agreement with Ono

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the signing of an agreement with Ono Pharmaceutical Co., Ltd. for the development and commercialization in Japan of KAI-4169, KAI's lead product candidate.

15 Sep 2011

Sickle cell trait does not increase risk of severe kidney disease in African-Americans

Researchers at Wake Forest Baptist Medical Center report that sickle cell trait is not a risk factor for the development of severe kidney disease in African-Americans.

15 Sep 2011

Tengion reinitiates enrollment in Neo-Urinary Conduit clinical trial for bladder cancer

Tengion, Inc. today announced that it has reinitiated enrollment of patients in the ongoing initial clinical trial of its lead product candidate, the Neo-Urinary Conduit, which is being evaluated in bladder cancer patients requiring a urinary diversion following bladder removal.

14 Sep 2011

AM-Pharma announces €29.2m series D round of financing

AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) for treatment of severe inflammatory diseases, today announced that it has raised €29.2m in Series D financing.

13 Sep 2011

Roundup: Ga. rejects rule to curb dental hygienists' work; Ohio high-risk pool faces higher than expected costs

The Georgia Board of Dentistry on Friday rejected a proposed rule that public health officials feared would have restricted dental hygienists' work with low-income patients. Several health groups had said the provision, if approved, would require a dentist to examine a patient before a hygienist can apply sealants, clean teeth and perform other preventive dental services in a public health setting.

13 Sep 2011

Dialysis News and Research

Latest Dialysis News and Research

Time trends in initiation of chronic dialysis in the U.S.

Takeda, Affymax announce data from multiple studies of peginesatide on anemia

Merck receives FDA approval for JUVISYNC to treat type 2 diabetes

Health Canada approves Trajenta (linagliptin) for type 2 diabetes

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Dialysis patients with kidney failure more likely to develop serious complications from flu

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

EMA CHMP adopts positive opinion for Soliris to treat atypical hemolytic uremic syndrome

E.U. CHMP issues positive opinion for use of Celgene's REVLIMID/dexamethasone MM drug

NYT: Ethics probe involves kidney transplant center, Rep. Berkley

First Edition: September 22, 2011

Long-term immunosuppressants improve survival for lupus patients with ESKD

Keryx completes enrollment in Zerenex Phase 3 long-term study for hyperphosphatemia

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

Demand for kidney transplant and dialysis increases due to diabetes prevalence

KAI enters KAI-4169 development and commercialization agreement with Ono

Sickle cell trait does not increase risk of severe kidney disease in African-Americans

Tengion reinitiates enrollment in Neo-Urinary Conduit clinical trial for bladder cancer

AM-Pharma announces €29.2m series D round of financing

Roundup: Ga. rejects rule to curb dental hygienists' work; Ohio high-risk pool faces higher than expected costs

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Dialysis News and Research

Latest Dialysis News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in